Claims for Patent: 7,446,195

Summary for Patent: 7,446,195

Title:	High affinity thiophene-based and furan-based kinase ligands
Abstract:	Inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
Inventor(s):	Deng; Yongqi (Newton, MA), Zhao; Lianyun (Burlington, MA), Shipps, Jr.; Gerald W. (Stoneham, MA), Curran; Patrick J. (Winthrop, MA), Siddiqui; M. Arshad (Newton, MA), Zhang; Rumin (Edison, NJ), McNemar; Charles W. (High Bridge, NJ), Mayhood; Todd W. (Randolph, NJ), Windsor; William T. (East Brunswick, NJ), Lees; Emma M. (Oakland, CA), Parry; David A. (Mountain View, CA)
Assignee:	Schering Corporation (Kenilworth, NJ)
Application Number:	11/505,263
Patent Claims:	1. A compound of formula (I) ##STR00249## or a pharmaceutically acceptable salt or ester thereof, wherein A is O or S; R.sup.20 is: ##STR00250## R.sup.21 is --C(O)N(R.sup.25R.sup.26); R.sup.23 is hydrogen, alkyl, alkoxy, alkoxyalkylamino, amino, alkylamino, dialkylamino, alkylheterocyclyl, alkylaryl, alkylheteroaryl, amido, aryl, alkoxyoxo, halo, heteroaryl, heterocyclyl, cyano, oxo, or aminoalkyl, wherein each of said alkyl, alkoxy, alkoxyalkylamino, amino, alkylamino, dialkylamino, alkylheterocyclyl, alkylaryl, alkylheteroaryl, aryl, alkoxyoxo, heteroaryl, heterocyclyl and aminoalkyl is either unsubstituted or optionally independently substituted with 1-3 independently selected P.sup.1 susbtituents, where P.sup.1 is alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, or alkylthio, or two P.sup.1 adjacent moieties together form an alkylenedioxy moiety fused to said aryl, heteroaryl, heterocyclyl ring they are attached to; R.sup.24 is hydrogen, halo, alkyl, alkylene, lower alkyl, aryl, heteroaryl, heterocyclyl, alkoxy, amino, aminoalkyl, alkylamino, dialkylamino, alkylthio, trihaloalkyl, wherein each of said alkyl, alkylene, lower alkyl, aryl, heteroaryl, heterocyclyl, alkoxy, amino, aminoalkyl, alkylamino, dialkylamino, alkylthio, trihaloalkyl is either unsubstituted or optionally independently substituted with 1-3 independently selected P.sup.1susbtituents, where P.sup.1 is alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, or alkylthio; or two R.sup.24 groups, which substitute atoms in a 1,2 or 1,3 arrangement on the phenyl ring said R.sup.24 is shown attached to together form --O--(CH.sub.2).sub.y--O--, --S--(CH.sub.2).sub.y--O--, --S--(CH.sub.2).sub.y--S, --CH.dbd.CH--CH.dbd.N--, --N.dbd.CH--CH.dbd.N--, or --S--CH.dbd.N-- where y is 1 or 2; or alternately R.sup.23 and R.sup.24 together form an aryl, heteroaryl or heterocyclyl ring with said aryl, heteroaryl or heterocyclyl ring being fused to the phenyl ring they are shown attached to; and R.sup.25 and R.sup.26 are linked together to form a six-membered heterocyclyl or heteroaryl. 2. The compound of claim 1, wherein R.sup.23 is hydrogen, alkyl, alkoxy, alkoxyalkylamino, amino, alkylamino, dialkylamino, alkylheterocyclyl, alkylaryl, alkylheteroaryl, amido, aryl, alkoxyoxo, halo, heteroaryl, heterocyclyl, cyano, oxo, or aminoalkyl wherein each of said alkyl, alkoxy, alkoxyalkylamino, amino, alkylamino, dialkylamino, alkylheterocyclyl, alkylaryl, alkylheteroaryl, aryl, alkoxyoxo, heteroaryl, heterocyclyl and aminoalkyl is either unsubstituted or optionally independently substituted with 1-3 independently selected P.sup.1 substituents, where P.sup.1 is alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, or alkylthio, or two P.sup.1 adjacent moieties together form an alkylenedioxy moiety fused to said aryl, heteroaryl, heterocyclyl ring they are attached to. 3. The compound of claim 1, wherein R.sup.23 is ##STR00251## 4. The compound of claim 1, wherein R.sup.23 is ##STR00252## 5. The compound of claim 1, wherein: R.sup.24 is hydrogen, halo, alkyl, alkylene, lower alkyl, aryl, heteroaryl, heterocyclyl, alkoxy, amino, aminoalkyl, alkylamino, dialkylamino, alkylthio, trihaloalkyl, wherein each of said alkyl, alkylene, lower alkyl, aryl, heteroaryl, heterocyclyl, alkoxy, amino, aminoalkyl, alkylamino, dialkylamino, alkylthio, trihaloalkyl is unsubstituted or optionally independently substituted with 1-3 independently selected P.sup.1 substituents, where P.sup.1 is alkyl, aryl, heteroaryl, heterocyclyl, cycloalkyl, alkoxy, amino, alkylamino, dialkylamino, or alkylthio; or two R.sup.24 groups, which substitute atoms in a 1,2 or 1,3 arrangement on the phenyl ring said R.sup.24 is shown attached to together form --O--(CH.sub.2).sub.y--O--, --S--(CH.sub.2).sub.y--O--, --S--(CH.sub.2).sub.y--S, --CH.dbd.CH--CH.dbd.N--, --N.dbd.CH--CH.dbd.N--, or --S--CH.dbd.N-- where y is 1 or 2. 6. The compound of claim 1, wherein R.sup.23 and R.sup.24 together form a ring moiety with said ring moiety being fused to the phenyl ring they are shown attached to, such that R.sup.20 becomes: ##STR00253## 7. The compound of claim 1, wherein R.sup.25 and R.sup.26 are linked together to form a six-membered heterocyclyl or heteroaryl, and R.sup.<is: ##STR00254## ##STR00255## 8. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of claim 1, or a pharmaceutically acceptable salt, or ester thereof, in combination with at least one pharmaceutically acceptable carrier. 9. The pharmaceutical composition of claim 8, additionally comprising one or more anti-cancer agents selected from the group consisting of cytostatic agent, cisplatin, doxorubicin, taxotere, taxol, etoposide, irinotecan, camptostar, topotecan, paclitaxel, docetaxel, epothilones, tamoxifen, 5-fluorouracil, methoxtrexate, temozolomide, cyclophosphamide, SCH 66336, R115777, L778,123, BMS 214662, gefitinib, erlotinib hydrochloride, antibodies to EGFR, imatinib, intron, ara-C, adriamycin, cytoxan, gemcitabine, Uracil mustard, Chlormethine, Ifosfamide, Melphalan, Chlorambucil, Pipobroman, Triethylenemelamine, Triethylenethiophosphoramine, Busulfan, Carmustine, Lomustine, Streptozocin, Dacarbazine, Floxuridine, Cytarabine, 6-Mercaptopurine, 6-Thioguanine, Fludarabine phosphate, Pentostatine, Vinblastine, Vincristine, Vindesine, Bleomycin, Dactinomycin, Daunorubicin, Doxorubicin, Epirubicin, Idarubicin, Mithramycin, Deoxycoformycin, Mitomycin-C, L-Asparaginase, Teniposide 17.alpha.-Ethinylestradiol, Diethylstilbestrol, Testosterone, Prednisone, Fluoxymesterone, Dromostanolone propionate, Testolactone, Megestrolacetate, Methylprednisolone, Methyltestosterone, Prednisolone, Triamcinolone, Chlorotrianisene, Hydroxyprogesterone, Aminoglutethimide, Estramustine, Medroxyprogesteroneacetate, Leuprolide, Flutamide, Toremifene, goserelin, Cisplatin, Carboplatin, Hydroxyurea, Amsacrine, Procarbazine, Mitotane, Mitoxantrone, Levamisole, Navelbene, Anastrazole, Letrazole, Capecitabine, Reloxafine, Droloxafine, or Hexamethylmelamine. 10. A compound of claim 1 in purified form.

Details for Patent 7,446,195

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978		2025-08-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2025-08-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2025-08-17
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2025-08-17